(Monday, 7/15/2019) 3:45 PM - 4:15 PM
Room: Exhibit Hall | Forum 5
Purpose: This study aims to test the feasibility to deliver simultaneous integrated boost to dominant intraprostatic lesions (DILs) for SBRT prostate treatment combining multi-parametric MRI simulation with MR Linear Accelerator (MR-Linac) treatment.
Methods: Three prostate patients were scanned on a 3T scanner using multi-parametric MRI, including T2 weighted, Diffusion weighted images (DWI) and Dynamic contrast enhanced imaging (DCE) prior to treatment. An experienced radiologist annotated DIL on each MR modality as well as the urethra on T2W images. A combined DIL CTV was created by integrating the volume from each modality on the T2W image. T2W images were fused to the planning MRI with focus on the prostate gland, and the CTV of the DIL was then propagated to the planning MRI (bSSFP, TE/TR=1.6ms/3.8ms). Prostate CTV and DIL CTV was expanded 3mm, and cropped away from critical organs to generate a PTV. An SBRT plan was retrospectively created for each patient following the NRG-GU005 protocol (36.25 Gy in 5 fractions, DIL SIB dose>8Gy). Total delivered dose was simulated using 5 daily MRI setup images and was compared with the initial SBRT plan dose.
Results: Dose constraints were met for all the organ at risks following NRG-GU005 for all three patients. Planning boost dose to the DILs were 46.19, 48.56, and 44.74Gy respectively for each patient. The prostate volume covered by the prescription dose was reduced by -8.91%, 0.34% and -0.25% in the accumulated dose compared to planning dose, while the dose covering 95% of DIL volume was reduced by -4.21%, -3.40% and -0.79% in accumulated dose.
Conclusion: We demonstrated it is feasible to treat SBRT prostate with escalated dose to the DILs (with PTV cropped 1mm away from rectum and bladder). Online daily adaptive planning is warranted to deliver prescription dose to both prostate gland and DIL.
Funding Support, Disclosures, and Conflict of Interest: The work was supported by a Research Scholar Grant, RSG-15-137-01-CCE from the American Cancer Society.
Keywords
Not Applicable / None Entered.
Taxonomy
Not Applicable / None Entered.
Contact Email
